Compare Fiverr International Ltd (FVRR) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Incyte Corporation — how do they compare? Fiverr International Ltd trades at $11.79 (market cap $404.45M), while Incyte Corporation trades at $115 (market cap $22.99B). The key difference: Incyte Corporation is far larger — about 56.8× Fiverr International Ltd's market cap, and Incyte Corporation is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals.
| FVRR | INCY | |
|---|---|---|
Market Cap | $404.45M | $22.99B |
Sector | Industrials | Health |
52-Week High | $26.67 | $118.52 |
52-Week Low | $9.62 | $67.38 |
Enterprise Value | $135.05M | $19.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $11.82, up 6.78% in the last session, showing strong momentum despite recent volatility. The stock exhibits bullish technical signals with moving averages supporting upward movement. Fundamentally, revenue grew to $430.91M in 2025 with improving net margins, while valuation ratios like P/E of 14.61 and P/S of 0.97 suggest potential undervaluation. Recent news highlights Fiverr's upcoming Q2 2026 earnings report on July 29, 2026, amid mixed sentiment from financial media.
The outlook for FVRR hinges on execution of its strategic shift and Q2 earnings performance. Opportunities include attractive valuation multiples and operational cash flow growth, but risks involve declining active buyers and ongoing legal investigations. Analyst consensus leans neutral with 41% buy ratings, reflecting cautious optimism pending clearer business traction.
INCY trades at $115.83, up 0.83% today, with a bullish technical signal from moving averages and strong fundamental performance including 2025 revenue of $5.14B and net income of $1.29B. Recent developments include positive Phase 1/2 data for VGA039 presented at ISTH 2026 and the acquisition of Vega Therapeutics, expanding its hematology portfolio. The stock shows robust profitability with a 26.71% net income margin and 30.82% ROE, while analyst consensus is a Buy with a $112.78 price target.
Outlook remains positive driven by pipeline advancements and earnings growth, though risks include clinical trial outcomes and regulatory hurdles. The current price above the consensus target suggests limited near-term upside, but continued execution could support further gains. Investors should weigh strong cash flow generation against competitive pressures in the biopharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
